Four‐Dimensional Machine Learning Radiomics for the Pretreatment Assessment of Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy in Dynamic Contrast‐Enhanced MRI
Open Access
- 28 May 2022
- journal article
- research article
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 57 (1) , 97-110
Abstract
Background: Breast cancer response to neoadjuvant chemotherapy (NAC) is typically evaluated through the assessment of tumor size reduction after a few cycles of NAC. In case of treatment ineffectiveness, this results in the patient suffering potentially severe secondary effects without achieving any actual benefit.Purpose: To identify patients achieving pathologic complete response (pCR) after NAC by spatio‐temporal radiomic analysis of dynamic contrast‐enhanced (DCE) MRI images acquired before treatment.Study type: Single‐center, retrospective.Population: A total of 251 DCE‐MRI pretreatment images of breast cancer patients.Field strength/sequence: 1.5 T/3 T, T1‐weighted DCE‐MRI.Assessment: Tumor and peritumoral regions were segmented, and 348 radiomic features that quantify texture temporal variation, enhancement kinetics heterogeneity, and morphology were extracted. Based on subsets of features identified through forward selection, machine learning (ML) logistic regression models were trained separately with all images and stratifying on cancer molecular subtype and validated with leave‐one‐out cross‐validation.Statistical tests: Feature significance was assessed using the Mann–Whitney U‐test. Significance of the area under the receiver operating characteristics (ROC) curve (AUC) of the ML models was assessed using the associated 95% confidence interval (CI). Significance threshold was set to 0.05, adjusted with Bonferroni correction.Results: Nine features related to texture temporal variation and enhancement kinetics heterogeneity were significant in the discrimination of cases achieving pCR vs. non‐pCR. The ML models achieved significant AUC of 0.707 (all cancers, n = 251, 59 pCR), 0.824 (luminal A, n = 107, 14 pCR), 0.823 (luminal B, n = 47, 15 pCR), 0.844 (HER2 enriched, n = 25, 11 pCR), 0.803 (triple negative, n = 72, 19 pCR).Data Conclusions: Differences in imaging phenotypes were found between complete and noncomplete responders. Furthermore, ML models trained per cancer subtype achieved high performance in classifying pCR vs. non‐pCR cases. They may, therefore, have potential to help stratify patients according to the level of response predicted before treatment, pending further validation with larger prospective cohorts.Evidence Level: 4Technical Efficacy: Stage 4Keywords
This publication has 41 references indexed in Scilit:
- Intratumor partitioning and texture analysis of dynamic contrast‐enhanced (DCE)‐MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapyJournal of Magnetic Resonance Imaging, 2016
- Breast DCE-MRI Kinetic Heterogeneity Tumor Markers: Preliminary Associations With Neoadjuvant Chemotherapy ResponseTranslational Oncology, 2015
- Pathological Complete Response in Neoadjuvant Treatment of Breast CancerAnnals of Surgical Oncology, 2015
- Identification of Intrinsic Imaging Phenotypes for Breast Cancer Tumors: Preliminary Associations with Gene Expression ProfilesRadiology, 2014
- The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information RepositoryJournal of Digital Imaging, 2013
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Breast Cancer Research and Treatment, 2011
- How to obtain the P value from a confidence intervalBMJ, 2011
- Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the WorldJournal of Clinical Oncology, 2006
- A Fuzzy C-Means (FCM)-Based Approach for Computerized Segmentation of Breast Lesions in Dynamic Contrast-Enhanced MR Images1Academic Radiology, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000